Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
暂无分享,去创建一个
[1] W. Whitmore,et al. Mithramycin in metastatic urogenital cancer. , 1967, The Journal of urology.
[2] D. Pinkel. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. , 1958, Cancer research.
[3] Mastrangelo Mj,et al. Phase I study of ICRF-159 (NSC-129943) in human solid tumors. , 1973 .
[4] H. Bisel,et al. Clinical studies with tubercidin administered by direct intravenous injection. , 1970, Cancer research.
[5] Homan Er. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. , 1972 .
[6] Frei E rd,et al. Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971 .
[7] D. Rall,et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.
[8] H. Hansen,et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.
[9] D. Rall,et al. Clinical studies of dichloromethotrexate (NSC 29630) , 1965, Clinical pharmacology and therapeutics.
[10] R. Adamson. METABOLISM OF ANTICANCER AGENTS IN MAN , 1971, Annals of the New York Academy of Sciences.
[11] V. Vaitkevicius,et al. Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses). , 1972, Cancer chemotherapy reports.
[12] G. Robertson,et al. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. , 1968, Canadian Medical Association journal.
[13] G. Falkson. Methyl-GAG (NSC-32946) in the treatment of esophagus cancer. , 1971, Cancer chemotherapy reports.
[14] J. Finklestein,et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. , 1973, Blood.
[15] G. Bryan,et al. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man. , 1969, Cancer research.
[16] A. Owens. Predicting anticancer drug effects in man from laboratory animal studies. , 1962, Journal of Chronic Diseases.
[17] T. Grage,et al. Clinical studies with tubercidin administered after absorption into human erythrocytes. , 1970, Cancer research.
[18] Luce Jk,et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970 .
[19] Bergsagel De,et al. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). , 1971 .
[20] E. Freireich,et al. Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. , 1969, Cancer chemotherapy reports.
[21] E J Freireich,et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.
[22] H. Skipper,et al. Experimental Evaluation of Potential Anticancer Agents: XII. Quantitative Drug Response of the SA180, CA755, and Leukemia L1210 Systems to a “Standard List” of “Active” and “Inactive” Agents , 1963 .
[23] A. Guarino,et al. Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology. , 1973, Cancer chemotherapy reports. Part 3.
[24] E. Frei,et al. Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971, Cancer chemotherapy reports.
[25] E. Henderson,et al. High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia. , 1972, Cancer chemotherapy reports.
[26] H. Skipper,et al. Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.
[27] A. Guarino,et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.
[28] J. Edmonson,et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. , 1965, Cancer research.
[29] B. Brodie. Part VI. Difficulties in extrapolating data on metabolism of drugs from animal to man , 1962 .
[30] C. Coltman,et al. Phase I experience with emetine hydrochloride (NSC 33669) as an antitumor agent , 1971, Cancer.
[31] F. Ansfield,et al. Phase I study of dibromodulcitol (NSC-104800). , 1971, Cancer chemotherapy reports.
[32] J. Finklestein,et al. Evaluation of a high dose cyclophosphamide regimen in childhood tumors , 1969, Cancer.
[33] For April. , 1903 .
[34] W. Regelson,et al. Clinical experience with methylglyoxal bis (guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas. , 1963, Cancer chemotherapy reports.
[35] J. Blom,et al. Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia. , 1972, Cancer chemotherapy reports.
[36] I. Todd,et al. The Design of Clinical Trials in Cancer Therapy , 1972, British Journal of Cancer.
[37] E. Homan. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. , 1972, Cancer chemotherapy reports. Part 3.
[38] R. Geran,et al. PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS , 1972 .